Project: A new therapeutic approach for severe bleeding
To develop a new treatment of severe bleeding to be used as prophylaxis or on demand. This innovative treatment, given systemically, prolongs the half-life of activated clotting factors at the site(s) of injury by neutralizing the main inhibitor of clotting in the blood, antithrombin III (AT). We will deliver 1) a humanized monoclonal antibody inhibiting AT; 2) cell lines producing the antibody; and 3) proof of concept for efficacy of the antibody in an animal model for severe bleeding.
| Acronym | ANTITHAB (Reference Number: 9763) |
| Duration | 01/04/2015 - 01/04/2018 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 3 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 21608 | Prothix BV | Coordinator | Netherlands |
| 21610 | Antitope Ltd | Partner | United Kingdom |
| 21611 | University Medical Center Utrecht | Partner | Netherlands |
| 21612 | GenOway | Partner | France |
| 23804 | Aristi Biotech BV | Partner | Netherlands |